GLP-1 based therapies: clinical implications for gastroenterologists.
about
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.The Role of Gut-brain Axis in Regulating Glucose Metabolism After Acute Pancreatitis.Roles of the gut in the metabolic syndrome: an overview.Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.
P2860
GLP-1 based therapies: clinical implications for gastroenterologists.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
GLP-1 based therapies: clinical implications for gastroenterologists.
@en
type
label
GLP-1 based therapies: clinical implications for gastroenterologists.
@en
prefLabel
GLP-1 based therapies: clinical implications for gastroenterologists.
@en
P2093
P2860
P1433
P1476
GLP-1 based therapies: clinical implications for gastroenterologists
@en
P2093
Daniel H van Raalte
Djuna L Cahen
Lennart Tonneijck
Mark H H Kramer
P2860
P304
P356
10.1136/GUTJNL-2015-310572
P407
P577
2016-01-19T00:00:00Z